PARENTERAL COMPOSITIONS OF CELECOXIB

(19)

(11)

EP 3 104 840 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	10.07.2019 Bulletin 2019/28

(45)	Mention of the grant of the patent:
	29.05.2019 Bulletin 2019/22

(21)	Application number: 15706617.6

(22)	Date of filing: 11.02.2015

(51)

International Patent Classification (IPC):

A61K 9/107^(2006.01)

A61K 31/415^(2006.01)

(86)	International application number:
	PCT/US2015/015379

(87)	International publication number:
	WO 2015/123272 (20.08.2015 Gazette 2015/33)

(54)	PARENTERAL COMPOSITIONS OF CELECOXIB PARENTERALE ZUSAMMENSETZUNGEN VON CELECOXIB COMPOSITIONS PARENTÉRALES DE CÉLÉCOXIB

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

11.02.2014 US 201461938338 P

(43)	Date of publication of application:
	21.12.2016 Bulletin 2016/51

(73)	Proprietor: Latitude Pharmaceuticals Inc.
	San Diego, CA 92131 (US)

(72)	Inventors:
	OKUMU, Franklin Morristown, NJ 07960 (US) CHU, Jan-Jon Carlsbad, CA 92010 (US) WEBB, Julie Ann San Diego, CA 92103 (US) SABINO, Rafael Anthony San Diego, CA 92116 (US) CHEN, Andrew Xian San Diego, CA 92121 (US)

(74)	Representative: Bates, Philip Ian
	Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS London E1 8QS (GB)

(56)

References cited: :

WO-A2-2008/032327
US-A1- 2009 263 486

WO-A2-2008/051186

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).